中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Magnetic resonance imaging-proton density fat fraction: A potential surrogate endpoint for nonalcoholic steatohepatitis clinical trials

DOI: 10.3969/j.issn.1001-5256.2021.06.047
  • Received Date: 2020-11-02
  • Accepted Date: 2020-12-04
  • Published Date: 2021-06-20
  • Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) is an imaging method that uses magnetic resonance technology to perform objective, quantitative, and noninvasive assessment of fat in the whole liver. This article mainly analyzes the correlation between MRI-PDFF value and the "gold index" nonalcoholic steatohepatitis (NASH) liver histological evaluation and explores its advantages and disadvantages as a noninvasive evaluation index for NASH clinical trials. Current studies have shown that MRI-PDFF, as an emerging noninvasive technique, is suitable for quantifying liver fat content and evaluating the degree of hepatic steatosis, but it cannot replace liver biopsy as a tool for the diagnosis of NASH. Meanwhile, the relative reduction in MRI-PDFF after drug intervention is not only highly correlated with the improvement of fat deposition, but also correlated with the improvement of inflammation and ballooning degeneration, and MRI-PDFF can predict the overall improvement of liver histology to a certain extent. Therefore, MRI-PDFF is considered a potential surrogate endpoint for NASH clinical trials.

     

  • [1]
    ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and Meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
    [2]
    Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association; National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, et al. Expert recommendations on standardized diagnosis and treatment for fatty liver disease in China (2019 revised edition)[J]. J Clin Hepatol, 2019, 35(11): 2426-2430. DOI: 10.3969/j.issn.1001-5256.2019.11.007.

    中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝与酒精性肝病学组, 等. 中国脂肪性肝病诊疗规范化的专家建议(2019年修订版)[J]. 临床肝胆病杂志, 2019, 35(11): 2426-2430. DOI: 10.3969/j.issn.1001-5256.2019.11.007.
    [3]
    MAO YM. Clinical trials of investigational new drugs for nonalcoholic steatohepatitis: challenges in design and practice[J]. J Clin Hepatol, 2017, 33(12): 2292-2295. DOI: 10.3969/j.issn.1001-5256.2017.12.007.

    茅益民. 非酒精性脂肪性肝炎新药临床试验: 设计和实践中的挑战[J]. 临床肝胆病杂志, 2017, 33(12): 2292-2295. DOI: 10.3969/j.issn.1001-5256.2017.12.007.
    [4]
    CAUSSY C, REEDER SB, SIRLIN CB, et al. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials[J]. Hepatology, 2018, 68(2): 763-772. DOI: 10.1002/hep.29797.
    [5]
    MAMIDIPALLI A, FOWLER KJ, HAMILTON G, et al. Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C)[J]. Eur Radiol, 2020, 30(9): 5120-5129. DOI: 10.1007/s00330-020-06858-x.
    [6]
    REEDER SB, CRUITE I, HAMILTON G, et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy[J]. J Magn Reson Imaging, 2011, 34(4): 729-749. DOI: 10.1002/jmri.22775.
    [7]
    JIANG LN, ZHAO JM. A clinical trial on the follow-up of nonalcoholic fatty liver disease: An evaluation of pathological endpoint[J]. J Clin Hepatol, 2018, 34(12): 2505-2508. DOI: 10.3969/j.issn.1001-5256.2018.12.004.

    蒋丽娜, 赵景民. 跟踪非酒精性脂肪性肝病的临床试验-病理学终点评价[J]. 临床肝胆病杂志, 2018, 34(12): 2505-2508. DOI: 10.3969/j.issn.1001-5256.2018.12.004.
    [8]
    PIAZZOLLA VA, MANGIA A. Noninvasive diagnosis of NAFLD and NASH[J]. Cells, 2020, 9(4): 1005. DOI: 10.3390/cells9041005.
    [9]
    GU J, LIU S, DU S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis[J]. Eur Radiol, 2019, 29(7): 3564-3573. DOI: 10.1007/s00330-019-06072-4.
    [10]
    QU Y, LI M, HAMILTON G, et al. Diagnostic accuracy of hepatic proton density fat fraction measured by magnetic resonance imaging for the evaluation of liver steatosis with histology as reference standard: A meta-analysis[J]. Eur Radiol, 2019, 29(10): 5180-5189. DOI: 10.1007/s00330-019-06071-5.
    [11]
    MIDDLETON MS, HEBA ER, HOOKER CA, et al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis[J]. Gastroenterology, 2017, 153(3): 753-761. DOI: 10.1053/j.gastro.2017.06.005.
    [12]
    TANG A, TAN J, SUN M, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis[J]. Radiology, 2013, 267(2): 422-431. DOI: 10.1148/radiol.12120896.
    [13]
    PERMUTT Z, LE TA, PETERSON MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease-MRI accurately quantifies hepatic steatosis in NAFLD[J]. Aliment Pharmacol Ther, 2012, 36(1): 22-29. DOI: 10.1111/j.1365-2036.2012.05121.x.
    [14]
    LE TA, CHEN J, CHANGCHIEN C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial[J]. Hepatology, 2012, 56(3): 922-932. DOI: 10.1002/hep.25731.
    [15]
    NOUREDDIN M, LAM J, PETERSON MR, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials[J]. Hepatology, 2013, 58(6): 1930-1940. DOI: 10.1002/hep.26455.
    [16]
    LOOMBA R, SIRLIN CB, ANG B, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)[J]. Hepatology, 2015, 61(4): 1239-1250. DOI: 10.1002/hep.27647.
    [17]
    JAYAKUMAR S, MIDDLETON MS, LAWITZ EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase Ⅱ trial of selonsertib[J]. J Hepatol, 2019, 70(1): 133-141. DOI: 10.1016/j.jhep.2018.09.024.
    [18]
    WILDMAN-TOBRINER B, MIDDLETON MM, MOYLAN CA, et al. Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis[J]. Gastroenterology, 2018, 155(5): 1428-1435.e2. DOI: 10.1053/j.gastro.2018.07.018.
    [19]
    RINELLA ME, TACKE F, SANYAL AJ, et al. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD[J]. Hepatology, 2019, 70(4): 1424-1436. DOI: 10.1002/hep.30782.
    [20]
    PATEL J, BETTENCOURT R, CUI J, et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis[J]. Therap Adv Gastroenterol, 2016, 9(5): 692-701. DOI: 10.1177/1756283X16656735.
    [21]
    LOOMBA R, NEUSCHWANDER-TETRI BA, SANYAL A, et al. Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH[J]. Hepatology, 2020, 72(4): 1219-1229. DOI: 10.1002/hep.31121.
    [22]
    HARRISON SA, BASHIR MR, GUY CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394(10213): 2012-2024. DOI: 10.1016/S0140-6736(19)32517-6.
    [23]
    HANNAH WN JR, TORRES DM, HARRISON SA. Nonalcoholic steatohepatitis and endpoints in clinical trials[J]. Gastroenterol Hepatol (NY), 2016, 12(12): 756-763.
    [24]
    BRIL F, BARB D, LOMONACO R, et al. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis[J]. J Hepatol, 2020, 72(3): 401-410. DOI: 10.1016/j.jhep.2019.09.018.
  • Relative Articles

    [1]Wenhui WANG, Xuhua DUAN, Hao LI, Shuguang JU, Manzhou WANG, Jianzhuang REN, Xinwei HAN. A cost-effect analysis of transarterial chemoembolization with CalliSpheres beads loaded with arsenic trioxide versus arsenic trioxide iodized oil emulsion in treatment of unresectable liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(9): 2125-2129. doi: 10.3969/j.issn.1001-5256.2021.09.024
    [2]Du YiChao, Zhang Hao, Zhong FuRui, Cheng HuanLi, Lai Li, Qian BaoLin, Tan Peng, Xia XianMing, Fu WenGuang. Protective effect of pinocembrin in a mouse model of liver injury induced by acetaminophen[J]. Journal of Clinical Hepatology, 2020, 36(3): 608-611. doi: 10.3969/j.issn.1001-5256.2020.03.027
    [3]Ha FuShuang, Han Tao, Liang Ning, Nie XinHua, Zhu ZhengYan. Effect of recombinant human granulocyte colony-stimulating factor on rats with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1565-1569. doi: 10.3969/j.issn.1001-5256.2019.07.028
    [4]Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
    [5]Zhang YongChao, Bi YanZhen, Fang Xiao, Wang QuanYi, Wang QuanQuan, Tang HuiXin, Kong LingBin, Chen Yu, Duan ZhongPing, Shu ZhenFeng, Hong Feng. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. Journal of Clinical Hepatology, 2019, 35(7): 1570-1575. doi: 10.3969/j.issn.1001-5256.2019.07.029
    [6]Wang Hao, He Cheng, Chen Hao, Ou YangZhongMin, Liu ZhiQiang. Value of Gd-EOB-DTPA-enhanced MRI in the assessment of liver function in dogs with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1576-1581. doi: 10.3969/j.issn.1001-5256.2019.07.030
    [7]Zhou QiFeng, Zhang LingQiang, Liao MengJiao, Pang MingQuan, Li MengXuan, Ren Li, Fan HaiNing. Establishment of a subcutaneous xenograft tumor model of alveolar echinococcosis in nude mice[J]. Journal of Clinical Hepatology, 2018, 34(3): 588-590. doi: 10.3969/j.issn.1001-5256.2018.03.028
    [8]Ji JunSong, Chen Ting, Wang Hui, Wang ChenYi, Zhu XinYing, Yin Hao, Fu ZhiRen. Effect of arsenic trioxide chemotherapy on survival time in liver cancer patients undergoing liver transplantation[J]. Journal of Clinical Hepatology, 2017, 33(9): 1745-1748. doi: 10.3969/j.issn.1001-5256.2017.09.023
    [9]Li Dong, Lu ZhongHua, Gan JianHe. Establishment of a rat model of early-stage liver failure and Th17/Treg imbalance[J]. Journal of Clinical Hepatology, 2016, 32(5): 928-932. doi: 10.3969/j.issn.1001-5256.2016.05.025
    [10]Chen Jing, Liu XiaoYan, Yang HaoZhen, Huang Kun, Hu JinHua, Xin ShaoJie. Study on p-p38 expression and its significance in liver tissues of mice with acute liver failure and patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 556-559. doi: 10.3969/j.issn.1001-5256.2015.04.019
    [11]Pang GuoJin, Chen ShuangJun, Zhao WeiHua, Liu TianHui, Wang Ping, You Hong, Cong Min. Dynamic change of hepcidin in liver fibrosis induced by CCl4 among mice[J]. Journal of Clinical Hepatology, 2015, 31(3): 418-423. doi: 10.3969/j.issn.1001-5256.2015.03.025
    [12]Gao ChengGuang, Chen RiXia. Clinical research on treatment of advanced primary liver cancer with combination of thymosin α1 and arsenic trioxide[J]. Journal of Clinical Hepatology, 2015, 31(4): 564-568. doi: 10.3969/j.issn.1001-5256.2015.04.021
    [13]Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028
    [14]Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
    [15]Jiang Han, Wang XueFeng, Wang ZiHao, Xu Bin, Shi WeiBin. The establishment of rabbit VX2 hepatic tumor model and the application of nano-scale microbubble contrast agent in the diagnosis of this model[J]. Journal of Clinical Hepatology, 2011, 27(7): 746-748.
    [16]Sun LinLin, Shi Jun, Hao JingHua, Ren WanHua, Yan ChunYing, Zhang Jie, Lin XiaoYan, Cui Bin. Effect of high-fat diet on establishment of a rat non-alcoholic steatohepatitis/liver fibrosis model[J]. Journal of Clinical Hepatology, 2011, 27(3): 254-257+272.
    [17]Ye LiHong, Wang ChongKui, Tian YueYang, Xu Yi, Zheng HaoJie, Shao ShiXiang, Dai ErHei. Effect of Ruangan Huajian granule on hepatic expression of PDGF - B in C57 mice with experimental hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1047-1050.
    [18]Song Yu, Yu Zheng, Fan YanHua, Yao ShuKun, Wang TaiLing. A rat model of hepatic veno-occlusive disease induced by the Gynura root water decoction[J]. Journal of Clinical Hepatology, 2011, 27(8): 860-864.
    [19]Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75.
  • Cited by

    Periodical cited type(10)

    1. 杨晓曼. γ-谷氨酰转移酶/血小板在乙肝肝硬化失代偿期患者中的表达及临床意义. 河南医学研究. 2024(08): 1407-1410 .
    2. 刘爱华,符建,陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究. 实用肝脏病杂志. 2023(05): 634-637 .
    3. 肖少伟,杜亚哲. γ-谷氨酰转移酶/胆碱酯酶比值与γ-谷氨酰转移酶/血小板比值对慢性乙型肝炎患者肝纤维化程度的预测效能. 实用医技杂志. 2023(11): 812-815 .
    4. 张玉婷,施欢,李虤,沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 .
    5. 桑阿利. APRI、Fib-4和Fibroscan联合诊断慢性乙型肝炎肝纤维化程度的价值. 甘肃医药. 2022(10): 896-898 .
    6. 王晔恺,于倩,姚燕珍,罗雯斌,洪开听,鲍舟君. 对数几率回归模型构建联合预测因子对慢性乙型肝炎患者早期肝硬化诊断的临床应用. 中国卫生检验杂志. 2021(01): 90-93+97 .
    7. 陈兴,梁小桃. 肝瞬时弹性成像与天冬氨酸转氨酶/血小板指数在慢性乙型肝炎合并脂肪肝患者肝纤维化诊断中的应用价值. 中国当代医药. 2021(11): 60-62 .
    8. 黄腊平,陈焰. 基于Fibroscan技术的柴胡疏肝散对非酒精性脂肪肝患者临床疗效分析. 清远职业技术学院学报. 2020(02): 35-38 .
    9. 栗红江,何久胜,胡素玲,何福亮,田彦卿,刘震霞. 声辐射力脉冲成像技术、瞬时弹性成像技术及天冬氨酸氨基转移酶与血小板比率指数联合检测乙型肝炎肝纤维化程度临床效能. 临床军医杂志. 2020(09): 1090-1091+1094 .
    10. 熊静,林登娜,翁伟镇,陈俊峰,曹会娟,张绍全,张静,高隽,林炳亮. FIB-4联合血清PCⅢ、ⅣC评估乙型肝炎病毒相关肝纤维化. 国际病毒学杂志. 2020(05): 403-406 .

    Other cited types(2)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 4.9 %FULLTEXT: 4.9 %META: 92.4 %META: 92.4 %PDF: 2.8 %PDF: 2.8 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 6.3 %其他: 6.3 %其他: 0.8 %其他: 0.8 %India: 0.2 %India: 0.2 %上海: 1.0 %上海: 1.0 %东莞: 0.2 %东莞: 0.2 %北京: 5.8 %北京: 5.8 %南京: 0.2 %南京: 0.2 %南宁: 0.2 %南宁: 0.2 %吉林: 0.6 %吉林: 0.6 %哥伦布: 0.2 %哥伦布: 0.2 %广州: 0.8 %广州: 0.8 %张家口: 2.3 %张家口: 2.3 %昆明: 0.5 %昆明: 0.5 %杭州: 0.3 %杭州: 0.3 %武汉: 0.8 %武汉: 0.8 %洛阳: 0.2 %洛阳: 0.2 %深圳: 0.3 %深圳: 0.3 %秦皇岛: 0.2 %秦皇岛: 0.2 %美国伊利诺斯芝加哥: 0.2 %美国伊利诺斯芝加哥: 0.2 %芒廷维尤: 42.4 %芒廷维尤: 42.4 %芝加哥: 0.2 %芝加哥: 0.2 %苏州: 0.2 %苏州: 0.2 %莫斯科: 1.5 %莫斯科: 1.5 %西宁: 33.2 %西宁: 33.2 %西安: 0.3 %西安: 0.3 %诺沃克: 0.2 %诺沃克: 0.2 %贵阳: 0.2 %贵阳: 0.2 %长春: 0.5 %长春: 0.5 %长沙: 0.2 %长沙: 0.2 %长治: 0.2 %长治: 0.2 %青岛: 0.2 %青岛: 0.2 %黄冈: 0.2 %黄冈: 0.2 %其他其他India上海东莞北京南京南宁吉林哥伦布广州张家口昆明杭州武汉洛阳深圳秦皇岛美国伊利诺斯芝加哥芒廷维尤芝加哥苏州莫斯科西宁西安诺沃克贵阳长春长沙长治青岛黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1347) PDF downloads(296) Cited by(12)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return